# Autoimmune foundations audit

Status: verified locally on 2026-09-24. Started following Cushing commit 0e8cce1. Earlier entries preserve review chronology; the closing entry supersedes their pending statuses. This is an editorial review, not independent pharmacist certification.

## Book and existing coverage

Read private extraction of printed 637/PDF 645. Existing orientation section `immune-inflammatory-transplant` supplies a brief infection-risk introduction, but not a developed explanation of inflammation markers versus autoantibody tests. Added a distinct `autoimmune-foundations` module, number 223, in Endocrine & Autoimmune. Six initial lessons, six original reasoning figures, six embedded checks and 15 focused questions are implemented and registered. This is not yet a completed chapter or module audit.

## Findings and implemented distinctions

The book groups ESR, CRP, RF and ANA as nonspecific inflammation tests. New lessons distinguish ESR/CRP from autoantibodies, interpret ANA positivity without diagnosing lupus, and retain the possibility of rheumatoid arthritis with negative RF. Neither test category replaces history and examination.

The book's uniform TB/HBV/HCV pretreatment rule is replaced by regimen-specific risk assessment. The new overview distinguishes TB screening, HBV prevention based on status, and antiviral referral for HCV RNA positivity. Exact drug-label examples and the broader toxicity/cancer discussion still need review and development before this overview is considered complete.

The live-vaccine steroid definition uses at least 14 days, including exactly 14, and distinguishes this vaccination criterion from adrenal-suppression and general infection-risk assessment. No single taper schedule is introduced. Steroid-taper discrepancies were addressed in the adrenal-pharmacology audit.

## Sources actually read

- MedlinePlus autoimmune diseases: summary, diagnosis and treatment sections, https://medlineplus.gov/autoimmunediseases.html .
- MedlinePlus ESR: mechanism, interpretation and confounders, https://medlineplus.gov/lab-tests/erythrocyte-sedimentation-rate-esr/ .
- MedlinePlus CRP: measurement, interpretation and distinction from hs-CRP, https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/ .
- MedlinePlus RF: measurement and positive/negative interpretation, https://medlineplus.gov/lab-tests/rheumatoid-factor-rf-test/ .
- ACR ANA patient guidance, February 2025: https://rheumatology.org/patients/antinuclear-antibodies-ana . Do not reproduce its imprecise suggestion that a negative ANA means no autoantibodies of any kind; module instead states reduced lupus likelihood in context, not exclusion of all autoimmune disease.
- CDC altered immunocompetence: corticosteroid and immune-therapy timing passages, https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html . Vaccine-specific schedules are not inferred from legacy entries elsewhere on that page.
- EULAR 2022 infection recommendations: primary abstract reproduced by author institution https://eprints.gla.ac.uk/286462/ and indexed recommendation passages. DOI 10.1136/ard-2022-223335. Publisher full-text opens failed; Parma repository PDF returned 403. No full-paper read claimed. Additional label-specific review remains pending.

## Validation and remaining work

Initial structural audit passes for 15 questions with no hard errors or source gaps; count-based advisories are not clinical evidence. A desktop/mobile figure and interaction run is active (local Chrome session 23456). Screenshots have not been inspected. Build, final scoring/reset, readability and integrated content closure remain pending.

The 70 kg, 20 mg/day, exactly 14-day example meets the absolute-dose and duration criteria. No calculated drug dose is prescribed. Final source reconciliation must also cover treatment diversity (including diseases managed through replacement or trigger avoidance), drug-specific infection/malignancy risks, and adequate original case coverage. Do not mark verified or commit as completed until this work and visual/application checks are closed.

Only audit-owned lines in the already-dirty module page should be staged when ready. No push or deployment performed. Prior exact-destination push authorization remains unresolved.

## First rendered pass

Session 23456 completed: all six sections on desktop and mobile returned HTTP 200, had one figure each, working navigation/check feedback/review anchors, and no page errors or horizontal overflow. Inspected all 12 captures. Desktop columns and mobile stacks are present with readable wrapping; floating global tools obscure some bottom content at captured positions. A scrolling accessibility/readability pass is still required. This first rendered pass does not close clinical coverage or final validation.


## Closing clinical review

Added treatment diversity using NIDDK celiac-treatment and Hashimoto-treatment sections: trigger avoidance and hormone replacement are not interchangeable with systemic immunosuppression. Read Rituxan label sections 2.1 and 5.3's HBV screening/monitoring passages; the overview now explicitly includes both HBsAg and anti-HBc and does not treat HBsAg negativity alone as clearance. Read Humira boxed warnings and the relevant 5.1/5.2 passages, including the nonmelanoma skin-cancer examination recommendation. Added label-specific infection and malignancy examples, without extrapolating one product's risk estimate to the entire class. These are targeted section reads, not claims of complete label review. Sources are linked in the module.

Read the final integrated six lessons, six checks, six original figures, all 19 questions, every answer, alternative and rationale. Coverage now includes clinical pattern; diagnostic/activity/safety distinctions; ESR/CRP versus ANA/RF; treatment diversity; TB and HBV/HCV decisions; vaccine safety/response and the exact 14-day threshold; infection versus flare; ongoing drug safety and malignancy surveillance. Detailed regimens remain in the disease modules. No proprietary figures or questions were copied. The chapter's associated steroid-taper discussion remains mapped to the previously completed adrenal-pharmacology review.

Independent numerical check: 70 kg exceeds the 10 kg boundary; 20 mg/day meets the absolute-dose criterion and 14 days meets the inclusive duration criterion. This is a vaccine-exposure classification, not an individualized steroid regimen.

## Closing validation

Final structural audit: 19 questions, no hard errors or source gaps. Two-case lesson advisories were reconciled with the focused foundation scope rather than filled with repetitive items. Production build exited successfully, compiled and generated 557 static pages. Previously inspected all 12 desktop/mobile figure captures; navigation, embedded feedback and review anchors passed for all six sections without page errors or horizontal overflow. Final practice runs scored all 10 answers correctly on each viewport and reset into a new attempt.

The first adapted readability script failed on a stale Cushing-only screenshot selector after practice passed. Corrected that QA-script selector; the completed rerun checked all 860 lesson/figure paragraph words on desktop and mobile with no inaccessible words. Floating controls can obscure the bottom of a figure at a fixed scroll position, but text remains available through scrolling. No unrelated global UI changes were staged.

Module verified locally; Chapter 46 still needs its final whole-chapter closure audit before changing its overall status. No deployment or push performed. Push remains subject to the previously recorded exact-destination authorization restriction.
